Searched for: author%3A%22Pruimboom-Brees%2C+I.%22
(1 - 2 of 2)
document
Reus, A.A. (author), Usta, M. (author), Kenny, J.D. (author), Clements, P.J. (author), Pruimboom-Brees, I. (author), Aylott, M. (author), Lynch, A.M. (author), Krul, C.A.M. (author)
An in vivo photomicronucleus test (MNT) using rat skin, the target organ for photoirritancy and carcinogenicity, was recently described. The assay was evaluated using fluoroquinolone (FQ) antibiotics with varying degrees of phototoxic potency (i.e. sparflocacin [SPFX], lomefloxacin [LOFX], ciprofloxacin [CIFX], levofloxacin [LEFX], gemifloxacin ...
article 2012
document
Reus, A.A. (author), Usta, M. (author), van Meeuwen, R.N.C. (author), Maas, W.J.M. (author), Robinson, S.A. (author), Kenny, J.D. (author), Pruimboom-Brees, I. (author), Clements, P.J. (author), Lynch, A.M. (author), Krul, C.A.M. (author), TNO Kwaliteit van Leven (author)
For pharmaceuticals, current regulatory guidance for photosafety testing states that studies are warranted for drug candidates that both absorb light in the range of 290-700 nm and that are either applied topically or reach the skin or eyes by systemic exposure. In contrast to standard genotoxicity evaluations, where a positive (or equivocal)...
article 2010